CompletedNCT00550576
Antibodies to Digoxin for Bipolarity
Medication studyAges 20–65Israel
Understand this study
Who was this study for?
Listed age limits: 20 years to 65 years.
- Listed locations
- HaifaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateOctober 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- Rambam Health Care Campus
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 20 Years to 65 Years
- Official registry ID
- NCT00550576
- Official title
Show the full official title
Antibodies to Digoxin for Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedHaifa
Questions about this study
Who is behind this study?
The study sponsor is Rambam Health Care Campus.
Did this study involve medication?
Yes. The study involved medication, including Digibind (Fab).
Who was this study for?
Listed age limits: 20 years to 65 years.
